Buehler Kevin 4

What Happened

• Kevin Buehler, a director of Precision BioSciences, received an award of 20,979 restricted stock units (RSUs) on June 3, 2026. The RSUs were granted as a derivative award with an acquisition price of $0.00 (code A on the Form 4). The RSUs represent a contingent right to receive one share of the company's common stock per RSU when they vest.

Key Details

• Transaction date: 2026-06-03; Form filed: 2026-06-05 (timely — within the Form 4 filing window).
• Grant quantity and price: 20,979 RSUs granted at $0.00.
• Derivative type: RSUs (each unit converts to one share upon vesting) — see footnote F1.
• Vesting schedule: RSUs vest on the earlier of (i) June 3, 2027 or (ii) the day before the issuer's next annual meeting after the grant date, subject to continued service (footnote F2).
• Shares owned after the transaction: not provided in the supplied data.

Context

• RSU grants are a form of compensation and do not involve an immediate cash purchase or sale; value is realized if and when RSUs vest and are settled in shares (or otherwise as company policy dictates). Such awards are common for directors and should not be read as an insider buy/sell signal by themselves.